The incorporation of BioPharma Ledger will enable clinical research organizations to achieve enhanced data sharing and storage capabilities.
FREMONT, CA: Modern clinical trial settings rely heavily on quick, easy, and transparent approaches to sharing massive troves of data with people located over vast distances. Requirements such as this have made pharmaceutical organizations to turn their gaze toward blockchain technology. It not only offers efficient means to store digital information in a decentralized base but also to share the data in the most secure manner.
Recently, ALTEN Calsoft Labs (ACL), a leading provider of enterprise digital transformation solutions and engineering R&D services, launched a blockchain clinical trial platform named BioPharma Ledger with Clinlogix. ACL has several years of expertise in developing digital, consulting, enterprise IT, and product engineering services across retail, healthcare, life sciences, telecom, manufacturing, energy & utilities, networking, semiconductor, and high-tech sectors. Clinlogix, on the other hand, is a global clinical research organization (CRO). It has branches in Europe, Asia, South America, and the US. The launch of the BioPharma Ledger made it the first practitioner to pilot and implement the blockchain platform for clinical trials.
ACL empowers organizations to innovate, integrate, and transform their businesses through the incorporation of groundbreaking technologies such as blockchain, digital interactive, cloud, mobility, AI & RPA, analytics, DevOps, IoT, and software-defined networking (SDN/NFV). ACL is part of ALTEN Group and is the second-largest global engineering services company with more than 33,700 employees across the world.
The new blockchain offering reinforces ACL’s commitment toward the digitalization of targeted areas in the industry. The new product will equip its customers with robust enterprise blockchain solutions for business initiatives ranging from business strategy to product development. Blockchain for clinical trials is one among its first blockchain offerings to the industry.
BioPharma Ledger will make a significant impact on clinical trials, enabling organizations to enhance and streamline many of the key processes involved. It will allow organizations to save cost and time, as well as achieve maximum efficiency. The blockchain platform utilizes BlockApps STRATO middleware platform. BlockApps is a founding member of the Enterprise Ethereum Alliance (EEA), a leading open-source initiative and the first blockchain platform that can be availed on Microsoft Azure, AWS, and Google Cloud. Blockchain in clinical trials will usher transparency, privacy, as well as traceability into the life sciences sector.